Skip to content
Altius – Lifestyle
Author:
PMGC Holdings Inc.
NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development
November 5, 2026
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
October 8, 2026
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
October 1, 2026
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
September 29, 2026
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
September 18, 2026
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
September 1, 2026
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
August 26, 2026
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
August 25, 2026
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
August 21, 2026
PMGC Holdings Inc. Announces Anticipated Reverse Stock Split
August 19, 2026
1
2
3
Next Page
→